BioCentury
ARTICLE | Clinical News

Bepreve: Additional Phase III data

November 16, 2009 8:00 AM UTC

Pooled data from 2 placebo-controlled, U.S. Phase III trials in 157 patients showed that 1.5% Bepreve was as effective in suppressing ocular itching in patients with more severe grades of itching as i...